These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
638 related articles for article (PubMed ID: 17261652)
1. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652 [TBL] [Abstract][Full Text] [Related]
2. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754 [TBL] [Abstract][Full Text] [Related]
3. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149 [TBL] [Abstract][Full Text] [Related]
4. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Angiolillo DJ; Capranzano P; Desai B; Shoemaker SB; Charlton R; Zenni MM; Guzman LA; Bass TA Thromb Res; 2009 Jul; 124(3):318-22. PubMed ID: 19012950 [TBL] [Abstract][Full Text] [Related]
5. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918 [TBL] [Abstract][Full Text] [Related]
6. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152 [TBL] [Abstract][Full Text] [Related]
7. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294 [TBL] [Abstract][Full Text] [Related]
8. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related]
9. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369 [TBL] [Abstract][Full Text] [Related]
10. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469 [TBL] [Abstract][Full Text] [Related]
11. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Neubauer H; Lask S; Engelhardt A; Mügge A Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186 [TBL] [Abstract][Full Text] [Related]
12. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878 [TBL] [Abstract][Full Text] [Related]
13. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E; Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251 [TBL] [Abstract][Full Text] [Related]
15. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393 [TBL] [Abstract][Full Text] [Related]
16. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496 [TBL] [Abstract][Full Text] [Related]
17. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150 [TBL] [Abstract][Full Text] [Related]
18. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828 [TBL] [Abstract][Full Text] [Related]
19. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization. Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS Platelets; 2010; 21(3):183-90. PubMed ID: 20201634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]